Systemic inflammatory regulators and risk of Alzheimer’s disease: a bidirectional Mendelian-randomization study

Abstract

Background Systemic inflammation has been suggested to be associated with Alzheimer’s-disease progression, although whether it is a cause or a downstream effect is still controversial. This study aims to assess the effect of systemic inflammatory regulators on Alzheimer’s disease within a bidirectional Mendelian-randomization design. Methods Genetic associations with Alzheimer’s disease were obtained from the largest and most up-to-date genome-wide association study (GWAS) (cases and proxy cases: 71 880; controls: 383 378) and with inflammatory regulators from two recent GWASs on the human proteome and cytokines. Estimates were obtained by inverse-variance weighting with sensitivity analyses using MR-Egger, weighted median and MR-PRESSO. Possible bias due to selective survival and competing risk was also considered. Results None of 41 systemic inflammatory regulators was associated with risk of Alzheimer’s disease with consistent results in validation analysis. Conversely, Alzheimer’s disease was suggestively associated with five systemic inflammatory regulators, i.e. basic fibroblast growth factor, granulocyte-colony-stimulating factor, interferon gamma, interleukin-13 and interleukin-7. Conclusion The systemic inflammatory regulators considered did not appear to be associated with the risk of Alzheimer’s disease. Conversely, specific systemic inflammatory regulators may be downstream effects of Alzheimer’s disease or consequences of common factors causing both inflammation and Alzheimer’s disease.

Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study

“…found that none of the genetically predicted 41 systemic inflammatory regulators were associated with the risk of AD. Conversely, AD was associated with five systemic inflammatory regulators, which implied that genetically predicted systemic inflammation may be a downstream effect of AD or a consequence of comorbidity factors ( 27 ). As inflammation is the core pathological mechanism of IBD, we should further verify whether AD leads to an increased risk of IBD.…”

The Causal Association Between Obesity and Primary Open-Angle Glaucoma: A Two-Sample Mendelian Randomization Study

“…To address the aforementioned issues, Katan et al (1986) introduced the concept of Mendelian randomization (MR) in 1986. MR is an epidemiological approach for investigating whether a causal effect exists between exposures and outcomes by using genetic variants as instrumental variables (IVs) ( Yeung & Schooling, 2021 ). This approach uses genetic variants that depend on strongly associated single-nucleotide polymorphisms (SNPs) from genome-wide association studies (GWASs) and makes use of the random classification of alleles during gametogenesis, which is similar to randomized clinical trials ( Qu et al, 2021 ).…”

Systemic inflammatory markers in relation to cognitive function and measures of brain atrophy: a Mendelian randomization study

“…As such, Mendelian randomization (MR) is an alternative approach using genetic instruments that are randomly allocated at conception as a proxy of exposure to infer the causality of life-long exposure on disease [14]. Three recent MR studies on inflammatory markers and Alzheimer's disease (AD), the most common type of dementia, have yielded inconsistent results [15][16][17]. Despite being done in large populations, these studies could still suffer from limited power caused by a limited number of cases.…”